BMRN - BioMarin Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
97.84
-2.56 (-2.55%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close100.40
Open100.30
Bid97.01 x 900
Ask102.00 x 1100
Day's Range96.80 - 100.84
52 Week Range75.81 - 106.20
Volume1,430,366
Avg. Volume1,126,423
Market Cap17.375B
Beta2.10
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateOct 24, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est119.35
Trade prices are not sourced from all markets
  • Estimates and Recommendations for Shire on September 19
    Market Realistyesterday

    Estimates and Recommendations for Shire on September 19

    Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017. Analysts expect Shire’s net adjusted income to increase to $4.68 billion in 2018 compared to its net adjusted income of $4.60 billion in 2017. Shire’s stock price has risen nearly 15.4% in the last 12 months, and it’s risen ~15.7% year-to-date in 2018.

  • See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRN

  • PR Newswire3 days ago

    BioMarin to Participate in Two Investor Conferences in October

    Cantor Fitzgerald Global Healthcare Conference on October 1 in New York City Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2 in New York City SAN RAFAEL, Calif. , Sept. 19, 2018 ...

  • See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRN

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRN

  • What Spark Therapeutics’ Valuation Trend Indicates
    Market Realist8 days ago

    What Spark Therapeutics’ Valuation Trend Indicates

    Of the 22 analysts covering Spark Therapeutics in September, 11 of them have recommended a “buy” or higher, and nine have recommended a “hold.” Two analysts have given the stock a “sell” or lower rating. The mean rating for Spark stock is 2.41 with a target price of $69.67, implying an upside potential of 18% over its closing price of $59.04 on September 13. Its peers Esperion Therapeutics (ESPR), Intercept Pharmaceuticals (ICPT), and Axovant Sciences (AXON) have mean ratings of 2.27, 2.41, and 2.71, respectively, and target prices of $72.68, $123.07, and $4.70, respectively.

  • Analysts Remain Bullish on BioMarin Pharmaceutical
    Market Realist8 days ago

    Analysts Remain Bullish on BioMarin Pharmaceutical

    Of the 23 analysts covering BioMarin Pharmaceutical (BMRN) in September, 19 of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for BioMarin stock is 1.78 with a target price of $119.35, implying an upside potential of 21.1% over its closing price of $98.58 on September 12.

  • BioMarin Pharmaceutical and Its Promising Research Pipeline
    Market Realist8 days ago

    BioMarin Pharmaceutical and Its Promising Research Pipeline

    Stocks focused on gene therapy have garnered strong investor interest in 2018. While some of them have been climbing steadily, others have received strong price corrections on pipeline news. In this series, we’ll analyze four companies: BioMarin Pharmaceutical (BMRN), Solid Biosciences (SLDB), Spark Therapeutics (ONCE), and uniQure (QURE).

  • When Will BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Become Profitable?
    Simply Wall St.8 days ago

    When Will BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Become Profitable?

    BioMarin Pharmaceutical Inc’s (NASDAQ:BMRN): BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company’s loss has recentlyRead More...

  • Why Analysts Remain Bullish on Sangamo Therapeutics
    Market Realist9 days ago

    Why Analysts Remain Bullish on Sangamo Therapeutics

    Its net loss per share was $0.17 in the second quarter of 2017. Six of them have given Sangamo stock a “buy” or higher rating, and one has rated it a “hold.” The mean rating for Sangamo stock is 1.71 with a target price of $27.83, implying an upside potential of 89.32% over its closing price of $14.70 on September 11. In comparison, peers Biogen (BIIB), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD) have mean ratings of 2, 1.78, and 2.15, respectively, and target prices of $389.20, $119.35, and $87.87, respectively.

  • Estimates and Recommendations for Bluebird Bio on September 6
    Market Realist16 days ago

    Estimates and Recommendations for Bluebird Bio on September 6

    Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017. Its EPS is expected to be -$10.83 in 2018. Analysts estimate net adjusted loss of $556.6 million in 2018.

  • Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy
    Market Realist16 days ago

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.

  • Sangamo's Zinc Fingers Fail Again. Time to Walk Away?
    Motley Fool16 days ago

    Sangamo's Zinc Fingers Fail Again. Time to Walk Away?

    Here's what investors need to know about the disappointing results Sangamo announced recently.

  • Investor's Business Daily17 days ago

    How This Biotech IPO Is Facing Off Vs. BioMarin In Metabolic Disease

    Rubius Therapeutics could rival BioMarin Pharmaceutical in treating a metabolic disorder but, first, the duo will face a dark horse candidate in the form of Synlogic.

  • How’s Alkermes Positioned Financially in September?
    Market Realist17 days ago

    How’s Alkermes Positioned Financially in September?

    In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017, which reflects ~39% growth year-over-year. In the second quarter, Alkermes generated revenues of $128.2 million as manufacturing and royalty revenues. Alkermes reported revenues of $109.8 from product sales in the second quarter—compared to $88.7 million in the second quarter of 2017.

  • PR Newswire17 days ago

    BioMarin Announces 20 Poster Presentations at Society for the Study of Inborn Errors of Metabolism (SSIEM) Symposium 2018

    Updated results from Phase 1/2 program for tralesinidase alfa (formerly BMN 250) SAN RAFAEL, Calif. , Sept. 5, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the ...

  • Why Sangamo Therapeutics Shot 33.7% Higher in August
    Motley Fool19 days ago

    Why Sangamo Therapeutics Shot 33.7% Higher in August

    Investor optimism is picking up ahead of important gene-editing trial data in September.

  • How BioMarin Pharmaceutical Is Positioned Financially in August
    Market Realist22 days ago

    How BioMarin Pharmaceutical Is Positioned Financially in August

    In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017, reflecting a ~17% YoY (year-over-year) growth. It reported net revenues of $746.3 million in the first half of 2018 compared to $621.2 million in the first half of 2017, reflecting a ~2% YoY growth.

  • How Analysts View BioMarin Pharmaceutical in August
    Market Realist22 days ago

    How Analysts View BioMarin Pharmaceutical in August

    On August 30, BioMarin Pharmaceutical (BMRN) stock closed at $99.26, which is ~7% below its 52-week high of $106.20 on August 2. It hit its 52-week low of $75.81 on April 6. 

  • Incyte’s Revenue Stream in Q2 2018
    Market Realistlast month

    Incyte’s Revenue Stream in Q2 2018

    Incyte (INCY) reported revenue of $521.5 million in the second quarter, a 59.7% rise YoY (year-over-year) compared to $326.4 million in the second quarter of 2017.

  • PR Newswirelast month

    BioMarin to Participate in Three Investor Conferences in September

    - Citi's 13th Annual Biotech Conference on September 5-6 in Boston - Morgan Stanley 16th Annual Global Healthcare Conference on September 12-14 in New York City - Jefferies Gene Therapy Summit on September ...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of BMRN earnings conference call or presentation 2-Aug-18 8:30pm GMT

    Q2 2018 Biomarin Pharmaceutical Inc Earnings Call

  • Motley Foollast month

    Is Spark Therapeutics a Bad News Buy?

    The company’s latest trial data failed to ignite a rally in its share price.

  • Motley Foollast month

    3 Tough-Luck Tumbles in Healthcare: Are They Buys?

    Spark Therapeutics, Rite Aid, and Alnylam Pharmaceuticals shares have dropped recently, but that doesn't necessarily make all three stocks worth buying.

  • Here’s What Tesaro’s Valuation Trend Indicates
    Market Realistlast month

    Here’s What Tesaro’s Valuation Trend Indicates

    Tesaro’s (TSRO) Phase 3 PRIMA trial of Zejula to evaluate it for the treatment of women with newly diagnosed ovarian cancer, irrespective of BRCA mutation status, has been completely enrolled. Its Phase 2 trial of Zejula in combination with an anti-PD-1 antibody in first-line non-small cell lung cancer is ongoing. The company expects to present data in the first half of 2019. In its immuno-oncology pipeline, Tesaro plans to submit a BLA (Biologic License Application) for TSR-042 in 2019.